HER-family gene amplification and expression in resected pancreatic cancer.

摘要: Abstract Aims Despite surgical resection, pancreatic cancer carries a poor prognosis. In search for new molecular therapeutic targets, we investigated the expression of HER-family and gene amplification HER-2 in adenocarcinomas different stages. Methods Tissue 45 resected patients was analyzed all 1-4 by immunohistochemistry assessed multiplex ligation-dependent probe chromogenic situ hybridization. The type surgery, location, stage grade tumor, as well involvement resection margins were correlated with HER-expressions univariate multivariate survival analysis performed. Results Normal tissue lacked HER1-2 expression, but did show HER3-4 expression. cancers, no membranous overexpression HER-1 seen nor found. HER-3, HER-4 is physiologically expressed normal pancreas loss cytoplasmic HER-3 33/45 (73%) 8/45 (18%) cancers. Cytoplasmic decreased from early to late ( p  = 0.05). not associated survival, or tumor grade. There statistically significant differences HER1-4 between papilla Vater n  = 13) non-papilla cancers  = 32). Multivariate showed only be independent prognostic value  = 0.015). Conclusions are overexpressed lost cancer. HER-targeted therapy supported HER-expression tumor.